What's New in the Pharma Sector: New Research on Amgen, Applied Genetic Technologies, Aptose, ARIAD, and Atara Biotherapeutics
NEW YORK, February 13, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Amgen (NASDAQ: AMGN), Applied Genetic Technologies (NASDAQ: AGTC), Aptose (NASDAQ: APTO), ARIAD (NASDAQ: ARIA), and Atara Biotherapeutics (NASDAQ: ATRA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AMGN Research Report: ( http://get.analystsreview.com/pdf/?c=Amgen&d=13-Feb-2015&s=AMGN ),
AGTC Research Report: ( http://get.analystsreview.com/pdf/?c=Applied%20Genetic%20Technologies&d=13-Feb-2015&s=AGTC ),
APTO Research Report: ( http://get.analystsreview.com/pdf/?c=Aptose&d=13-Feb-2015&s=APTO ),
ARIA Research Report: ( http://get.analystsreview.com/pdf/?c=ARIAD&d=13-Feb-2015&s=ARIA ),
ATRA Research Report: ( http://get.analystsreview.com/pdf/?c=Atara%20Biotherapeutics&d=13-Feb-2015&s=ATRA ).
============
--
Analyst Update: Positive Study Results, Appointments, Scheduled Events, and Quarterly Results
Reviewed by: Rohit Tuli, CFA®
Major U.S. and European equity indices rallied to multiyear or record highs on Thursday after a cease-fire between Russian separatists and Ukrainian forces, and unexpectedly aggressive stimulus by Sweden's central bank, cheered global markets. The Nasdaq Composite surged past multiyear highs reached in December to levels last seen in March 2000, closing up 1.18% higher at 4,857.1. Dow was up 0.62% to 17,972.38, while the S&P 500 rose 0.96% to close at 2,088.48. In Europe, shares reversed early losses on a broadly positive raft of results, with 62% of companies meeting or beating earnings forecasts. Sentiments in the European markets were boosted by the Ukraine peace agreement, Swedish economic stimulus measures and hope for a Greek debt deal. The Greek stock market jumped 6.7% after the ECB approved extra emergency finance for Greek banks. In Asia, Japanese stocks rallied to their highest settlement in more than seven years as a weaker yen supported many export-related shares. Most other Asian markets too ended on a positive note.
Amgen Inc. (Amgen) has reported positive top-line results from Phase 3 Study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (Adalimumab) in patients with moderate-to-severe rheumatoid arthritis. The said study met its primary and key secondary endpoints.
Applied Genetic Technologies Corporation (Applied Genetic Technologies) has appointed Stephen W. Potter as its Vice President and Chief Business Officer. Mr. Potter, who has more than 15 years of experience as a Senior Executive in the biotechnology industry, succeeds Daniel L. Menichella, who resigned from his position with the Company to pursue another opportunity.
Aptose Biosciences, Inc. (Aptose), a clinical-stage biotechnology company, announced the appointment of Dr. Bradley Thompson to the Audit Committee. With this appointment, the Company has regained compliance with Listing Rule 5605, as notified by the NASDAQ Stock Market. The listing rule requires a Company to maintain at least three independent members on the Audit Committee.
ARIAD Pharmaceuticals, Inc.'s (ARIAD) M.D. Chairman and CEO Harvey J. Berger to present an overview of the Company's business at the Leerink Global Healthcare Conference, to be held in New York City on Thursday, February 12, 2015, at 3:30 p.m. ET. The Company has also scheduled to report its Q4 2014 and full-year 2014 results and issue its 2015 financial guidance on Thursday, February 19, 2015, before the markets open.
Atara Biotherapeutics, Inc. (Atara Biotherapeutics) posted a net loss of $5.9 million or $4.20 per diluted share, in the third quarter of 2014, compared to a net loss of $2.5 million, or $2.59 per diluted share, during Q3 2013. Research and development expenses, including costs paid to Amgen, Inc., more than doubled to $4.2 million, from $1.7 million in the comparable previous year quarter.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article